Abstract | BACKGROUND: METHODS: From 1980 to 2006, 431 patients underwent 640 postchemotherapy surgical procedures to remove lung (n = 159, 36.8%), mediastinal (n = 136, 31.6%), or both lung and mediastinal (n = 136, 31.6%) metastases within 2 years of chemotherapy. Multiple variables potentially predictive of survival were analyzed. RESULTS: The overall median survival was 23.4 years, with 295 (68%) patients alive and well after an average follow-up of 5.6 years. There was no survival difference in patients who underwent removal of lung or mediastinal metastases. Pathologic categories of resected residual disease were necrosis (21.5%), teratoma (52.7%), persistent NSGCT (15.0%), and degenerative non- germ cell cancer (10.1%). Multivariable analysis identified older age at time of diagnosis (p = 0.001), non- germ cell cancer in testes specimen (p = 0.004), and pathology of residual disease (p < 0.001) as significantly predictive of survival. CONCLUSIONS: Patients who undergo resection of residual lung or mediastinal disease for metastatic testicular NSGCT as a planned approach after cisplatin-based chemotherapy have overall excellent long-term survival. Survival is equivalent comparing hematogenous and lymphatic routes of metastases but depends on the pathology of the resected disease. These results justify an aggressive surgical approach, particularly to remove residual teratoma in the lung or mediastinum after chemotherapy, including multiple surgical procedures if necessary.
|
Authors | Kenneth A Kesler, Laura E Kruter, Susan M Perkins, Karen M Rieger, Katherine J Sullivan, Matthew L Runyan, John W Brown, Lawrence H Einhorn |
Journal | The Annals of thoracic surgery
(Ann Thorac Surg)
Vol. 91
Issue 4
Pg. 1085-93; discussion 1093
(Apr 2011)
ISSN: 1552-6259 [Electronic] Netherlands |
PMID | 21440128
(Publication Type: Journal Article)
|
Copyright | Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. |
Topics |
- Adolescent
- Adult
- Aged
- Child
- Humans
- Lung Neoplasms
(mortality, secondary, therapy)
- Male
- Mediastinal Neoplasms
(mortality, secondary, therapy)
- Middle Aged
- Neoplasms, Germ Cell and Embryonal
(mortality, secondary, therapy)
- Retrospective Studies
- Survival Rate
- Testicular Neoplasms
(mortality, pathology, therapy)
- Young Adult
|